Innovent Biologics IPO First-Day: Take Money off the Table
Despite a recent spell of lacklustre early-stage biotech flotations that have slumped post-IPO, Innovent Biologics Inc (1801 HK)'s shares popped...
514 Views
Samsung BioLogics Update
Recent developments in Samsung Biologics Co., (207940 KS)'s business have been mixed with a negative skew. First, partner Merck & Co Inc (MRK...
523 Views
Innovent Biologics IPO Preview: Limited Upside on China's PD-1 Drug Market Compared to BeiGene
Innovent Biologics Inc (1641475D HK) is the fourth pre-profit biotech firm to IPO in Hong Kong since Ascletis Pharma Inc (1672 HK), BeiGene Ltd...
686 Views
S&P 500: Outlook Constructive but Concerns Remain
As the S&P 500 nears the 2,873 January high - a critical hurdle - short-term Sector leadership changes give us reason for pause. While we...
295 Views
Celltrion: Manufacturing Risks Remain
Celltrion Inc (068270 KS) continues to struggle with meeting the USFDA's standards for Good Manufacturing Practices. The agency issued a Form 483...
408 Views